Clinical trial
Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell…
NCT00284687 · Hadassah Medical Organization, Other · Completed
Key facts
| NCT number | NCT00284687 |
|---|---|
| Title | Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients |
| Official title | Phase III Study Evaluating the Safety and Efficacy of Artesunate in Preemptive Treatment of Human Cytomegalovirus Disease in Stem Cell Transplant Recipients |
| Lead sponsor | Hadassah Medical Organization, Other |
| Collaborators | Institut für Klinische und Molekulare Virologie University of Erlangen-Nürnberg Medical School |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Infections |
| Intervention type | Drug |
| Interventions | Artesunate |
| Enrollment | 20 |
| Start date | Jul 1, 2006 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Feb 1, 2006 |
| Last update posted | Jun 10, 2010 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: